One of the most significant logistical shifts in oncology is the move from hospital-based intravenous infusions to oral chemotherapy regimens. This transition is being fueled by patient preference for the convenience and privacy of home-based treatment, as well as the need for healthcare systems to reduce the burden on oncology clinics. Oral formulations allow for a more consistent "metronomic" dosing schedule, which can be less taxing on the body than high-dose periodic infusions. To support this trend, the pharmaceutical industry is developing sophisticated digital adherence tools and smart packaging that help patients manage their medication cycles safely and effectively outside of a clinical setting.

According to research into the Chemotherapy Market, the "Oral Route of Administration" segment is projected to grow at a rapid pace as more blockbuster drugs lose patent protection and transition into accessible oral formats. Online pharmacies are emerging as a lucrative distribution channel, providing attractive discounts and home delivery services that facilitate access for a growing geriatric population. This shift is also encouraging the development of "low-dose multi-drug" protocols, which utilize advanced computer simulations to optimize dose timing. By reducing the physical and financial barriers to treatment, the expansion of oral chemotherapy is making high-quality oncology care more sustainable on a global scale.